145 related articles for article (PubMed ID: 12505548)
1. Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
Akagi T; Ushinohama K; Kage Y; Ishizaki T; Makinosumi T; Yamauchi A; Taguchi Y; Inoue K; Yukawa E; Higuchi S; Ohdo S
Life Sci; 2003 Jan; 72(10):1183-97. PubMed ID: 12505548
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice.
Ohdo S; Makinosumi T; Ishizaki T; Yukawa E; Higuchi S; Nakano S; Ogawa N
J Pharmacol Exp Ther; 1997 Dec; 283(3):1383-8. PubMed ID: 9400014
[TBL] [Abstract][Full Text] [Related]
3. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
Sadzuka Y; Hirotsu S; Hirota S
Cancer Lett; 1998 May; 127(1-2):99-106. PubMed ID: 9619864
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
[TBL] [Abstract][Full Text] [Related]
5. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Morton CL; Iacono L; Hyatt JL; Taylor KR; Cheshire PJ; Houghton PJ; Danks MK; Stewart CF; Potter PM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):629-36. PubMed ID: 15918039
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
[TBL] [Abstract][Full Text] [Related]
8. In vivo cell cycle synchronization of the murine sarcoma 180 tumor following alternating periods of hydroxyurea blockade and release.
Tomita K; Plager JE
Cancer Res; 1979 Nov; 39(11):4407-11. PubMed ID: 498073
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice.
Miki T; Nonomura N; Takaha N; Nishimura K; Kojima Y; Sawada M; Okuyama A
Int J Urol; 1998 Jul; 5(4):370-3. PubMed ID: 9712447
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
11. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
[TBL] [Abstract][Full Text] [Related]
12. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Guichard S; Hennebelle I; Bugat R; Canal P
Biochem Pharmacol; 1998 Mar; 55(5):667-76. PubMed ID: 9515577
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
Jansen WJ; Kolfschoten GM; Erkelens CA; Van Ark-Otte J; Pinedo HM; Boven E
Int J Cancer; 1997 Dec; 73(6):891-6. PubMed ID: 9399672
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
Cao S; Rustum YM
Cancer Res; 2000 Jul; 60(14):3717-21. PubMed ID: 10919639
[TBL] [Abstract][Full Text] [Related]
15. [Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats].
Takasuna K; Kasai Y; Kitano Y; Mori K; Kakihata K; Hirohashi M; Nomura M
Nihon Yakurigaku Zasshi; 1995 Jun; 105(6):447-60. PubMed ID: 7557733
[TBL] [Abstract][Full Text] [Related]
16. Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Ann N Y Acad Sci; 1996 Dec; 803():173-80. PubMed ID: 8993510
[No Abstract] [Full Text] [Related]
17. Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11.
Takeda S; Shimazoe T; Kuga H; Sato K; Kono A
Biochem Biophys Res Commun; 1992 Oct; 188(1):70-7. PubMed ID: 1329748
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Ikuno N; Soda H; Watanabe M; Oka M
J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
Lavelle F; Bissery MC; André S; Roquet F; Riou JF
Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
[TBL] [Abstract][Full Text] [Related]
20. Circadian rhythm of irinotecan tolerability in mice.
Filipski E; Lemaigre G; Liu XH; Méry-Mignard D; Mahjoubi M; Lévi F
Chronobiol Int; 2004 Jul; 21(4-5):613-30. PubMed ID: 15470958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
